We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a phase 3 trial of a three-drug combination for the treatment of chronic obstructive pulmonary disease met eight out of its main objectives.
The Anglo-Swedish pharmaceutical company said that the results of the Kronos trial, which compared a combination of budesonide, glycopyrronium and formoterol with a number of rival therapies, was published in the journal The Lancet Respiratory Medicine.
The three-drug cocktail called PT010 showed a significant reduction of exacerbations in patients with the disease compared with rival therapy, the company said.
AstraZeneca said it plans on making a first regulatory submission for the drug in the second half of the year.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 17, 2018 02:49 ET (06:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
